CODEXIS, INC. (CDXS) stock: key figures, P/E, revenue and dividend
Materials · United States · ISIN US1920051067
CODEXIS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 70.39 m USD |
| Gross profit | 61.05 m USD |
| Operating income | -41.74 m USD |
| EBIT | -46.55 m USD |
| Net income | -43.97 m USD |
| Diluted EPS – continuing operations | -0.50 USD |
Full history since 2006, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CODEXIS, INC.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
More stocks
- Senhwa Biosciences, Inc. (6492.TWO)
- Edesa Holding SA (EDSH.BA)
- TEAM INC (TISI)
- Gyldendal ASA (GYL.OL)
- e-LITECOM CO. Ltd (041520.KQ)
- Fluent, Inc. (FLNT)
- Yinfu Gold Corp. (ELRE)
- Surteco Group (SUR.DE)
- enCore Energy Corp. (EU)
- Eastern Union Interactive Corp. (7738.TWO)
- Elentec Co. Ltd (054210.KQ)
- Chime Ball Technology Co Ltd (1595.TWO)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.